Sign In

Brandon Staglin

Co-Founder, Chief Advocacy & Engagement Officer at One Mind | Advancing neuropsychiatric research, driving better care for mental health, leading patient-centered services, & dismantling discrimination through media.

Brandon Staglin, the Co-founder and Chief Advocacy & Engagement Officer at One Mind, leverages his extensive background in communications and advocacy, coupled with his personal journey of schizophrenia recovery, to spearhead mental health research and care aimed at transforming lives.

His firsthand experience with schizophrenia and recovery fuels his passion for advocating for enhanced data-driven, networked, and continually evolving prevention and early intervention services for youth contending with severe psychiatric conditions.

Brandon is the innovator behind One Mind's ASPIRe program, designed to enhance recovery rates by enhancing early access to quality care. He played a pivotal role in the passing of California laws AB 1315 and SB 1004, which allocate resources and ensure accountability for mental health services statewide.

As the visionary behind the One Mind Brain Waves webcast, Brandon Staglin disseminates knowledge and motivation to destigmatize brain health and facilitate recovery from psychiatric ailments across the nation.

Brandon Staglin holds a Master of Science (MS) in Health/Health Care Administration/Management from the University of California, San Francisco, and has completed programs in nonprofit leadership, new strategies, and engineering science at prestigious institutions like Stanford University, Georgetown University McDonough School of Business, and Dartmouth College.

Throughout his career, Brandon has held various roles in esteemed organizations such as serving on the Evaluation Advisory Board for the CalMHSA Help@Hand Project at the University of California, Irvine - College of Medicine, being a Council Member at the National Institute of Mental Health (NIMH), and assuming leadership positions at One Mind and Staglin Family Vineyard.

His proficiency spans IT management, marketing communications, ethical, legal, and social issues advocacy, and configuration engineering, reflecting his diverse skill set and his commitment to advancing mental health awareness and support.

Brandon Staglin continues to be a driving force in the mental health advocacy landscape, striving to foster a society that prioritizes and normalizes brain health while supporting individuals on their journey to recovery and well-being.

Highlights

Aug 17 · linkedin

It’s outrageous that a third of us with schizophrenia remain stuck in recovery limbo due to the debilitation of negative symptoms. Thus, I felt honored to soeak at the FDA‘s first meeting on Evaluating the Negative Symptoms of Schizophrenia in Clinical Trials, on behalf of One Mind. I love to inspire scientists to remember how important their work is, and this meeting was key as it marked the start of a push for the research community to tackle these understudied symptoms in earnest.

Key takeaways:

Gregory Strauss showed results indicating that people with schizophrenia ranked the five “negative symptoms” in order of life impact as avolition, anhedonia, asociality, blunted affect and alogia. Successfully treating avolition (the reduction of motivation) consistently also addressed the other negative symptoms, indicating underlying links.

Eric Jarvis of McGill revealed how intercultural misunderstandings can lead scientists to medicalize healthy disengagement that can arise due to historic discrimination patterns. He emphasized the need for scientific cultural humility and the use of culturally sensitive assessment tools for research to treat negative symptoms in diverse populations.

Laura Swett discussed how to ensure research incorporates patient perspectives on such critical topics as what types of measurable clinical changes can meaningfully improve lives.

Sophia Vinogradov, Christoph Correll and I recognized that although testing psychosocial rehabilitation as an adjunct with experimental drugs may complicate clinical trials, such combinations may produce synergistically better outcomes for people recovering from negative symptoms.

I look forward to this meeting’s influence in accelerating better treatments for schizophrenia!

Jul 3 · linkedin

As a highly stigmatized condition, schizophrenia doesn’t get enough public attention–though the The Johns Hopkins University (JHU) Schizophrenia Center, led by One Mind Rising Star Awardee Akira Sawa, is working to change that. Last week, I had the privilege of speaking at the JHU Schizophrenia Symposium. Here are some fascinating insights and advancements shared at the event:

Key Insights:

  • Early detection and intervention are crucial for schizophrenia treatment, with clozapine showing promise for treatment-resistant cases.
  • Raquel Gur highlighted the complexity of psychosis, likening it to earthquakes in the brain.
  • Insights from the Philadelphia Neurodevelopmental Cohort revealed that 20% of participants with psychosis also experienced anxiety or depression.
  • Scott Stroup’s research showed higher rates of dementia and suicide among schizophrenia patients.
  • Employment and functionality remain significant challenges, with only 17% of people with schizophrenia employed.
  • Sabina Berretta discussed how malfunctioning in the brain’s glial cells can lead to decreased synaptic plasticity and impairments in emotion regulation and cognitive flexibility.

Research Updates and Advancements:

  • The Schizophrenia Center’s renewed Conte Center Grant focuses on the olfactory system and negative symptoms, with positive results from deep brain stimulation (DBS) for hallucinations.
  • Positive outcomes were reported with specific DBS settings for auditory hallucinations, and early studies suggest cognitive improvements from sulforaphane, a compound found in broccoli seeds.
  • Advancing precision medicine by categorizing patients based on medication response and brain protein aggregation was emphasized.
  • The symposium underscored the complexity of schizophrenia and the need for tailored interventions to improve the lives of those affected. The shared knowledge and ongoing research efforts continue to inspire hope for more effective treatments and better quality of life for individuals with schizophrenia. #SchizophreniaResearch #MentalHealth #JHUSymposium #PrecisionMedicine #Neuroscience #MentalHealthAwareness
Brandon Staglin
Add to my network

Location

Napa, California, United States